News & Events
Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals
VICTORIA, November 05, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces…
ImmunoPrecise Adopts Shareholder Rights Plan
VICTORIA, October 18, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces…
ImmunoPrecise Exhibiting at European Antibody Congress in Basel, October 15-19, 2019
ImmunoPrecise Antibodies will attend the Festival of Biologics held at the Congress Centre, Basel October 15-19th. The Festival of Biologics is a combination of four incredible conferences, the European…
ImmunoPrecise Strengthens Board of Directors with Antibody Business Leader, Brian Lundstrom
VICTORIA, October 3, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the…
ImmunoPrecise Antibodies Appoints Biotech Industry Executive Dr. Stefan Lang as Chief Business Officer
VICTORIA, October 1st, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global…
ImmunoPrecise’s Talem Therapeutics Enters into an LOI with AgonOx Pharma in the Advancement of Novel, Immuno-Oncology Therapeutics
VICTORIA, September 24, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces…
ImmunoPrecise Launches Abthena™ Bispecific Platform And Artemis™ Intelligence Metadata (AIM)
VICTORIA, September 23, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB: IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces…
ImmunoPrecise to Lead Roundtable and Present Poster at 2019 West Coast Antibody Therapeutics Xchange
As innovative leaders in the field of antibody discovery, we are pleased to sponsor and lead group discussions at the 2019 West Coast Antibody Therapeutics Xchange. The unique format…
ImmunoPrecise Exhibiting at Discovery on Target in Boston, MA, on September 16-19
ImmunoPrecise Antibodies will participate in the 17th Annual Discovery on Target (DOT) being held Boston, MA September 16-19. With over 1,300 attendees and a variety of keynote speakers, training…
ImmunoPrecise Antibodies’ Annual Revenues Increase 100% to $10,926,268 Million
VICTORIA, August 28, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) today reports its financial results for the year ended April 30,…
Shareholder Lab Visit: ImmunoPrecise Antibodies – Canada
ImmunoPrecise Antibodies Ltd invites our shareholders to visit our Victoria Lab on Wednesday, August, 14th, followed by a social at Canoe Brewpub in Downtown Victoria. Shareholders will have the…
ImmunoPrecise’s Wholly Owned Talem Therapeutics Announces the Creation of its Scientific Committee
VICTORIA, August 1, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB PINK: IPATF) announces the launch of its High Value Target Scientific Committee…
ImmunoPrecise Antibodies Announces Immuno-oncology Discovery Collaboration with Entos Pharmaceuticals
VICTORIA, June 12, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF), an industry leader in the discovery of novel, therapeutic monoclonal…
ImmunoPrecise Guarantees Success for Customers of Their Well-Established B cell Select™ Antibody Discovery Platform
VICTORIA, June 26, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF), the industry leader in the discovery of novel, therapeutic monoclonal…
ImmunoPrecise Attending & Exhibiting at Antibody Engineering & Therapeutics Europe 2019
The ImmunoPrecise Antibodies team will be exhibiting at Antibody Engineering & Therapeutics (AET) Europe 2019 in Amsterdam, NL from June 11th-13th, 2019. AET Europe is the industry’s European meeting for…
ImmunoPrecise’s Diversified Offerings Spark Surge in Requests for use of Nine Different Transgenic Animal Strains on Innovative Service Platforms in B cell Select™️ and DeepDisplay™️
VICTORIA, May 30, 2019 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTCQB PINK: IPATF) announces that its proprietary, high-throughput B cell and phage display platforms have…
ImmunoPrecise Antibodies’ Subsidiary U-Protein Express Announces Exclusive Agreement as Global Supplier for Wnt-Surrogate-Fc Growth Factor
VICTORIA, APRIL 25, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) U-Protein Express, a wholly-owned ImmunoPrecise Antibodies subsidiary, in Utrech, Netherlands,…
ImmunoPrecise to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference
VICTORIA, April 16, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announced today that Jennifer Bath, President and CEO of ImmunoPrecise…
ImmunoPrecise Appoints Andy Nixon to Board of Directors
VICTORIA, April 11, 2019 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces that it has appointed Andy Nixon, Vice President of Biotherapeutics Molecule Discovery at…
TetraGenetics and ImmunoPrecise extend collaboration by signing multi-target service agreement for the Discovery of Therapeutic Antibodies
VICTORIA, April 9th, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce the extension of its collaboration with…
ImmunoPrecise Attending & Exhibiting at #PEGS 19 in Boston, April 8-11
The 2019 Protein Engineering Summit (PEGS) in Boston is the industry’s preeminent event that inspires innovative biotherapeutic protein drug development. Plan to meet the IPA team at our booth (#622)…
ImmunoPrecise Antibodies Ltd. Announces Trading on OTCQB® Venture Market
Victoria, British Columbia, Canada, April 03, 2019 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that its common shares…
ImmunoPrecise Antibodies Leverages Proprietary Technology and Expertise to Create Talem Therapeutics
VICTORIA, April 4, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces it has formed a wholly-owned, Cambridge, Massachusetts-based subsidiary, Talem…
ImmunoPrecise Launches DeepDisplay(™) Antibody Discovery Platform – ImmunoPrecise Launches Large-Scale Discovery Program with US Pharma Company
VICTORIA, April 2,2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces the expansion of their service offerings in therapeutic antibody discovery…
ImmunoPrecise Antibodies Reports Record Q3 2019 Financials Results – Revenues Up 228% For The First 9 Months of Fiscal 2019
VICTORIA, March 27, 2019 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “ImmunoPrecise”) (TSX VENTURE: IPA) (OTC PINK: IPATF) today reports its financial results for Q3 ended January 31, 2019….
Meet Us at European Antibody Therapeutics Xchange
ImmunoPrecise to Lead Scientific Round-table Discussion and Poster Session at hubXchange’s European Antibody Therapeutics event. At hubXchange’s European Antibody Therapeutics event, held in Munich on March 21st, Dr. Debby Kruijsen…
ImmunoPrecise Antibodies Announces Resignation of Jos Raats, as Managing Director of ModiQuest Research BV
VICTORIA, March 15, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) today announces that Jos Raats, Ph.D., has resigned from the…
ImmunoPrecise Antibodies Announces DTC Eligibility
VICTORIA, February 28, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that its common shares are now…
Meet Us at the Americas Antibody Congress 2019
ImmunoPrecise will be exhibiting at the Americas Antibody Congress 2019 at Festival of Biologics, a multi-streamed, co-located conference & technology exhibition March 4 – 5, 2019 at the Grand…
ImmunoPrecise Antibodies Receives Subcontract to Produce Rabbit Monoclonal Antibodies
VICTORIA, February 21, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) has received a five-year Indefinite Delivery/Indefinite Quantity (ID/IQ) subcontract from…
ImmunoPrecise Antibodies Collaborates with FIND to Help Advance New TB Diagnostic Test
VICTORIA, February 19, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces the publication of the results of a research collaboration…
Second US Office for ImmunoPrecise Antibodies, Ltd. in Cambridge, Massachusetts.
VICTORIA, February 14, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) has announced that they have opened a new subsidiary office…
ImmunoPrecise Antibodies Ltd. Increases Antibody Discovery Capabilities with Addition of Integrated Laboratory Equipment for High-throughput Antibody Screening
VICTORIA, February 4th, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) has announced the purchase of its second state-of-the-art Intellicyt® iQue…
ImmunoPrecise Appoints Lisa Helbling as Chief Financial Officer
VICTORIA, January 14, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that it has appointed Lisa Helbling as…
Meet Us at PepTalk 2019
ImmunoPrecise will be attending PepTalk 2019, the Protein Science Week, from January 14-18th, 2019. PepTalk is the largest annual gathering of protein science researchers in the world. The conference…
ImmunoPrecise Antibodies Will Be in San Francisco During J.P. Morgan Healthcare Conference Week January 7-10, 2019
VICTORIA, January 3, 2019 / – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announced today IPA will be in San Francisco during the J.P….
ImmunoPrecise Hires Jason Orloske as Vice President Operations
VICTORIA, Dec. 26, 2018 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce Jason Orloske has accepted the position of Vice President of Operations for…
Meet Us at Antibody Engineering & Therapeutics 2018
ImmunoPrecise will be attending Antibody Engineering & Therapeutics 2018, the annual meeting of The Antibody Society, where you can find the latest science, technologies and partners in antibody engineering, immunobiology,…
ImmunoPrecise Antibodies Ltd. Discusses Target Customer Base and Growth Drivers in an Interview with StockNewsNow
ImmunoPrecise’s CEO and President, Dr. Jennifer Bath spoke with SNNLive at the SmallCap Discoveries Conference 2018 in Vancouver. Check Out the Video to Find out More On: The overview…
Meet Us at the 10th Annual PEGS Summit Europe
ImmunoPrecise, ModiQuest Research, and U-Protein Express will be attending the 10th annual PEGS Summit Europe. PEGS (Protein & Antibody Engineering Summit) is the largest European event for all aspects…
ImmunoPrecise Antibodies Ltd. Announces Genetic Immunization Platform
Victoria, British Columbia, Canada, October 29, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is excited to expand its immunization services through…
European Antibody Congress 2018
ImmunoPrecise at European Antibody Congress 2018 ImmunoPrecise is excited to announce that we will be a part of the European Antibody Congress within the Festival of Biologics in Basel, Switzerland from…
ModiQuest to Offer Ligand’s OmniAb Service in Europe
Victoria, British Columbia, Canada, October 15th, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announces that ModiQuest® Research, an ImmunoPrecise Company, is…
ImmunoPrecise Signs Large Pharma Antibody Development Agreement
Victoria, British Columbia, Canada, October 9th, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is pleased to announce that it has signed…
ImmunoPrecise Announces Phage Display-Based Antibody Discovery Platforms
Victoria, British Columbia, Canada, October 2nd, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) announced the addition of in-house and custom phage…
Immunoprecise Antibodies’ Q1 Revenues Increase 386% Over Q1 2017
October 1st, 2018 – Victoria, British Columbia. IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise”) (TSX Venture: IPA, Pink Sheets: IPATF) today reports its financial results for Q1 ended July 31, 2018. The…
ImmunoPrecise Closes Oversubscribed Private Placement Raising $9.1m
Victoria, British Columbia, Canada, September 28, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has closed its previously announced non-brokered private…
US West Coast Antibody Engineering Xchange 2018
ImmunoPrecise at US West Coast Antibody Engineering Xchange 2018 ImmunoPrecise is excited to announce that we will be attending hubXchange’s US West Coast Antibody Engineering Xchange in San Diego on…
The Centre for Drug Research and Development (CDRD) selected ImmunoPrecise’s Chief Scientific Officer, Dr. Deanna Dryhurst as member of the CDRD Academy Executive Institute
Victoria, British Columbia, Canada, September 21st, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) is proud to announce that our CSO, Dr….
Meet with ImmunoPrecise at the 16th Annual Discovery on Target
ImmunoPrecise is excited to be exhibiting at this year’s Discovery on Target conference from September 25th to 28th in Boston, MA. Visit booth #213 at the Sheraton Boston, and…
ImmunoPrecise and Harbour Antibodies Announce Technology Co-offering Agreement for Next-Generation Fully-human Antibody Discovery
Co-offering Agreement combines ImmunoPrecise’s advanced hybridoma plus B cell screening and sorting services with Harbour Antibodies’ patented H2L2 transgenic mouse platform Victoria, British Columbia, Canada, August 30th, 2018 –…
ImmunoPrecise Antibodies’ Annual Revenues Increase 106% to 5.4 Million
August 29, 2018 – Victoria, British Columbia. IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise”) (TSX Venture: IPA, Pink Sheets: IPATF) today reports its financial results for the year ended April 30, 2018. …
ImmunoPrecise Increases Private Placement Financing to $7 Million
Victoria, British Columbia, Canada, August 28, 2018 – IMMUNOPRECISE ANTIBODIES LTD.(“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has increased its previously announced non-brokered private placement financing…
ImmunoPrecise Announces $2 Million Financing
Victoria, British Columbia, Canada, August 22, 2018 – IMMUNOPRECISE ANTIBODIES LTD.(“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it proposes to complete a non-brokered private placement financing of…
ImmunoPrecise Announces the Resignation of Director
Victoria, British Columbia, Canada, August 20, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that Mr. Guy Champagne, has resigned from his position…
ImmunoPrecise Accelerates the Launch of its European, Full-service, B-cell Facility
VICTORIA, July 18, 2018 /CNW/ – To meet global demand, IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) accelerates the launch of its European B-cell facility expansion at its…
ImmunoPrecise Closes Private Placement Financing
Victoria, British Columbia, Canada, June 19, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has closed its previously announced non-brokered private…
Antibody Engineering & Therapeutics Europe June 5th-7th, 2018 – Meet with ImmunoPrecise & ModiQuest Research
ImmunoPrecise & ModiQuest Reseach B.V. will be exhibiting at the upcoming Antibody Engineering & Therapeutics Europe in Amsterdam! Come visit us at Booth #10 Featured Services B cell Selection…
ImmunoPrecise Increases Private Placement Financing
Victoria, British Columbia, Canada, May 30, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has increased its previously announced non-brokered private…
ImmunoPrecise Announces Private Placement Financing
Victoria, British Columbia, Canada, May 29, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it proposes to complete a non-brokered private placement…
BIO International Convention June 4th-7th, 2018 – Meet with ImmunoPrecise
ImmunoPrecise will be at the upcoming BIO International Convention in Boston and looks forward to meeting with you. Featured Services B cell Selection Technologies Advanced Hybridoma Development Preferred OmniAb®…
ImmunoPrecise Appoints Jennifer Bath to Board of Directors and Expands Senior Leadership to Further Global Growth
Victoria, British Columbia, Canada, May 24, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that, as part of its annual review of management…
ImmunoPrecise Opens U.S. Headquarters in Fargo, North Dakota
Victoria, British Columbia, Canada, May 18, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the opening of its U.S. Headquarters in Fargo,…
ImmunoPrecise Opens New Full Service B-Cell Facility
Victoria, British Columbia, Canada, April 27, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the opening of its new, innovative full service B-cell…
ImmunoPrecise Announces Oversubscription To Debenture Financing
Victoria, British Columbia, Canada, April 6, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces it has completed a final tranche to its debenture (the “Debentures”)…
ImmunoPrecise Acquires Modiquest Research BV
Immediately Accretive by Adding EBITDA of Approximately C$750,000 with Increased Synergies, Scale and Efficiency Strategic Acquisition Allows ImmunoPrecise to Provide Comprehensive and Next Generation Antibody Therapeutic Discovery Victoria, British…
Meet ImmunoPrecise at the Protein & Antibody Engineering Summit (PEGS) in Boston
ImmunoPrecise will be exhibiting at the upcoming PEGS Summit conference, April 30th to May 4th in Boston. Meet the Team Come say hello to our team at booth 618. Here are the…
ImmunoPrecise Antibodies Delivers Record Quarterly Revenue of $1.723 Million and Increases Gross Margins to 54%
March 28, 2018 – Victoria, British Columbia. IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX Venture: IPA, OTC PINK: IPATF) today reports its financial results for the third quarter…
ImmunoPrecise Enters Into Definitive Agreement To Acquire Modiquest Research BV
Victoria, British Columbia, Canada, March 16, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “ImmunoPrecise”) (TSX VENTURE: IPA)(OTC PINK: IPATF) is pleased to announce that it has entered into…
ImmunoPrecise Appoints New President and CEO
Victoria, British Columbia, Canada, February 8, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the appointment of Dr. Jennifer Bath, as the new President…
ImmunoPrecise Antibodies Grants Stock Options
VICTORIA, January 27, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSXV:IPA, Pink Sheets:IPATF) reports that, pursuant to the Company’s Stock Option Plan, the Board of Directors has authorized the…
ImmunoPrecise Engages San Francisco Based Lightpath Capital as A Key Partner in its Financing Strategy
Victoria, British Columbia, Canada, January 18, 2018 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has engaged LightPath Capital, Inc. (“LightPath”) to act…
ImmunoPrecise Antibodies Attending J.P. Morgan Healthcare Conference Week January 8-11, 2018
ImmunoPrecise will be attending the J.P. Morgan 36th Annual Healthcare Conference running from January 8-11, 2018 in San Francisco, California. Thirty-five years ago, J.P. Morgan launched Wall Street’s premier…
ImmunoPrecise Antibodies Reports Second Quarter Results
December 29, 2017 – Victoria, British Columbia. IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSXV: IPA, Pink Sheets: IPATF) today reports its financial results for the second quarter ended October 31,…
ImmunoPrecise Adds Scientific Depth To Its Board Of Directors
Victoria, British Columbia, Canada, December 18, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) is pleased to announce the appointment of Dr. Robert Burke to…
Meet ImmunoPrecise at Antibody Engineering & Therapeutics 2017
If you will be attending the Antibody Engineering & Therapeutics show, make sure to stop by booth #219! This is a great opportunity to meet with our scientists, discuss…
ImmunoPrecise to Acquire ModiQuest Research BV
Victoria, British Columbia, Canada, December 7, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with…
ImmunoPrecise Realigns Senior Management
Victoria, British Columbia, Canada, November 20, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces the realignment of its senior management team as Dr. James…
ImmunoPrecise Antibodies Reports Q1 2018 Results
ImmunoPrecise Develops Humanizing Platforms to Significantly Grow Core Business.Increases Operational Efficiency and Expands Capacity to Scale Quickly September 29, 2017 – Victoria, British Columbia. IMMUNOPRECISE ANTIBODIES LTD. (the “Company”)…
Immunoprecise Awarded First Commercial Humanized Antibody Project From Established Biotech Company And Grants Stock Options
Victoria, British Columbia, Canada, September 18, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “ImmunoPrecise”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has been awarded its first significant…
ImmunoPrecise Antibodies Announces Dr. Oren Beske Joining The Executive Leadership Team and AGM Results
Victoria, British Columbia, Canada, September 7, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), is pleased to announce that Oren Beske, Ph.D. has joined the…
ImmunoPrecise Announces R&D Success Using The OmniAB® Platform to Develop Fully Human Antibodies
Victoria, British Columbia, Canada, August 29, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), announces the Company is now an approved contract research organization (“CRO”)…
ImmunoPrecise Antibodies Reports 2017 Annual Results – Revenues Up 39% Over Fiscal 2016
Victoria, British Columbia, Canada, August 24, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSX VENTURE: IPA)(OTC PINK: IPATF) yesterday reported its financial results for the fourth quarter…
ImmunoPrecise Completes Acquisition of U-Protein and Private Placement of $5.25 Million
Victoria, British Columbia, Canada, August 23, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has completed the acquisition of U-Protein Express BV (“U-Protein”)…
ImmunoPrecise Signs Definitive Agreement with U-Protein
Victoria, British Columbia, Canada, August 11, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that, further to its news release dated July 4, 2017, it…
ImmunoPrecise Announces Expansion Into Humanizing Technologies and Platforms
Victoria, British Columbia, Canada, August 3, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) is pleased to announce that it has completed significant steps that enhance…
ImmunoPrecise Increases Financing to $5.25 Million
Victoria, British Columbia, Canada, August 2, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), in conjunction with its acquisition of U-Protein Express B.V., is pleased to…
ImmunoPrecise Increases Financing to $5.1 Million
Victoria, British Columbia, Canada, July 24, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), in conjunction with its acquisition of U-Protein Express B.V., is pleased to…
ImmunoPrecise To Acquire U-Protein and Announces $4,000,000 Financing
Victoria, British Columbia, Canada, July 4, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF) announces that it has signed a binding letter of intent with U-Protein…
Immunoprecise Antibodies Opens New Antibody Production Laboratory To Increase Manufacturing Capacity
Victoria, British Columbia, Canada, June 5, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”)(TSX VENTURE: IPA)(OTC PINK: IPATF), is pleased to announce the opening of its new 3,200 square foot state…
Immunoprecise Begins Humanized Antibody Development
Victoria, British Columbia, Canada, April 11, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”)(TSX VENTURE: IPA)(OTC PINK: IPATF), is pleased to announce the launch of a new research initiative.
Immunoprecise Antibodies Reports Q3 2017 Financial Results –Revenues Up 70% For The First Nine Months Of Fiscal 2017
Victoria, British Columbia, Canada, March 30, 2017 – IMMUNOPRECISE ANTIBODIES (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), today reports its financial results for the third quarter ended January 31,…
Meet IPA at the 30th Annual CSI Conference April 7-10, 2017 – Banff, AB
Join us at the 30th Annual Canadian Society for Immunology Conference in beautiful Banff, AB, this April 7-10, 2017. Date: April 7 – 10, 2017 Location: The Banff Centre, Banff,…
Immunoprecise Adds Dr. David Kroeger As Senior Scientist; New Us Trading Symbol
Victoria, British Columbia, Canada, March 9, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: IPATF), a life sciences technology and product company engineering custom antibodies, is…
Immunoprecise Appoints Contact Financial for Investor Relations and Launches New Website For Its Custom Antibody Services
Victoria, British Columbia, Canada, March 1, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA)(OTC PINK: TQURF), a life sciences technology and product company engineering custom antibodies, announced…
Immunoprecise Antibodies Issues Letter To Shareholders
Victoria, British Columbia, Canada, January 23, 2017 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company”) (TSX VENTURE: IPA), a life sciences technology and product company supplying custom antibodies, today announced that…